Important note: Information in this article was accurate in 2007. The state of the art may have changed since the publication date.
Important note: Information in this article was accurate in 2007. The state of the art may have changed since the publication date.
Reuters NewMedia - November 13, 2007
Maggie Fox
Amy Nunn and colleagues at the Harvard School of Public Health analyzed the costs of individual AIDS drugs in Brazil and found that generic drugs produced in Brazil were usually more expensive than similar drugs made elsewhere.
But, by negotiating for lower patented drug prices, Brazil had lowered the overall average costs for AIDS drugs.
"Brazil's AIDS treatment program has been cited widely as the developing world's largest and most successful AIDS treatment program," they wrote in their report, published in the Public Library of Science journal PLoS Medicine.
"The program guarantees free access to highly active antiretroviral therapy (HAART) for all people living with HIV/AIDS in need of treatment."
The program, begun in 1996, now covers 180,000 Brazilians and also provides free condoms. It has helped slow infection rates to a stable 0.6 percent of the population -- similar to rates seen in the United States.
Brazil produces generic versions of eight non-patented AIDS drugs.
It has used the threat of generic drugs to persuade companies to lower their prices for expensive AIDS drugs, even though Brazil has signed on to World Trade Organization patent agreements.
Last May, Brazil broke the patent on Merck & Co. Inc.'s (MRK.N: Quote, Profile, Research) efavirenz to import a cheaper generic version from India instead.
Other countries, including Canada and Italy, have also used a clause in World Trade Organization rules to flout drug patents in the name of public health.
In July, Brazil worked out an agreement with Abbott Laboratories Inc. (ABT.N: Quote, Profile, Research) to cut the price of its drug Kaletra by 29.5 percent.
071113
RE071115
Copyright © 2007 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Contact Reuters.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .